Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

Travere Therapeutics received a USPTO Notice of Allowance for U.S. Patent Application No. 19/253,120 covering certain methods of using FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS). If issued, the patent would strengthen U.S. intellectual-property protection for FILSPARI and may support the drug's longer-term commercial positioning.

Analysis

The market value of this development is contingent on two unproven links: whether the eventual claims survive examination in commercially meaningful breadth, and whether FILSPARI obtains an approvable FSGS label. A method-of-use patent does not repair the prior clinical/regulatory hurdle in FSGS, so it should not meaningfully alter near-term probability-weighted revenue until Travere discloses a credible FDA path, labeling discussion, or additional efficacy package. The relevant diligence items are the issued claim language, expiry date, patent-term adjustment, and whether the patent is listed in the Orange Book after any approval.

If FSGS commercialization becomes viable, the strategic benefit is less the isolated patent and more improved negotiating leverage with payers and potential generic challengers across a small, concentrated prescriber base. Conversely, narrow claims may be designed around by competitors or generics through label carve-outs, limiting the practical exclusivity value despite a favorable headline. Investors should view this as modest downside protection to terminal value rather than a driver of 2026 estimates.

Near term, TVTX could see a sentiment-driven bid, but biotech holders are likely to demand regulatory de-risking rather than assign a higher multiple solely to intellectual-property optionality. Over the next 1-3 months, any incremental FDA engagement, FSGS development update, or confirmation of broad claims would be a better catalyst than patent issuance itself; over 6-18 months, the thesis turns on whether FSGS can become a second durable renal franchise. The bullish interpretation is underdone only if the patent reaches well beyond a narrow dosing or patient-selection method and materially extends exclusivity beyond the core composition-of-matter horizon.

Key Decisions for Investors

• No standalone directional trade on the notice: maintain TVTX at benchmark/monitor status until the issued patent’s claims and expiration are public; a notice of allowance alone is insufficient to revise revenue or terminal-value assumptions.
• For existing TVTX longs, use any patent-driven strength over the next several sessions to avoid adding unless price action is accompanied by new FSGS regulatory guidance; the key falsifier is management failing to articulate a viable approval path or disclosing claims too narrow to constrain label-carved-out competition.
• Set an event alert for FDA meeting outcomes, a revised FSGS filing strategy, and Orange Book listing. Upgrade only if those disclosures establish both an approvable label pathway and exclusivity extending materially beyond existing protection.
• If an issued patent confirms broad FSGS-use claims with long remaining life, consider a 6-12 month TVTX long sized as binary regulatory optionality, not patent monetization; risk should be capped because adverse FDA feedback can overwhelm any incremental IP value.